Celltrion’s Omlyclo is interchangeable with Xolair to treat the same conditions: asthma, chronic rhinosinusitis, food allergy ...

Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor ...

Rhumbline Advisers reduced its stake in Castle Biosciences, Inc. (NASDAQ:CSTL – Free Report) by 2.5% in the 4th quarter, according to the company in its most recent filing with the Securities & ...

Breast cancer patients who underwent postmastectomy breast reconstruction had lower sexual well-being scores compared with ...

Esophageal cancer, particularly esophageal squamous cell carcinoma (ESCC), is one of the most prevalent digestive malignancies, with a 5-year survival rate of only 20%. Although some cancer ...

Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that ...

BeiGene (NasdaqGS:ONC) experienced a significant 29% price increase over the last quarter, supported by the FDA approval of TEVIMBRA for treating esophageal squamous cell carcinoma, a key development ...

The US Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr), in combination with platinum-containing ...

The US Food and Drug Administration (FDA) has approved BeiGene’s Tevimbra (tislelizumab-jsgr) along with platinum-containing ...

The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing ...

The FDA has approved Tevimbra (tislelizumab) for use in combination with chemotherapy as first-line treatment for unresectable or metastatic, PD-L1-positive ESCC.

The FDA has approved Tislelizumab (Tevimbra) plus platinum-based chemotherapy as a first-line treatment for adult patients ...